How many mg in 20gm?

I. INTRODUCTION

Ibogaine (12-methoxyibogamine, NIH 10567, Endabuse) will be one of the psychoactive indolealkaloids found inside the West African shrub, Tabernanthe iboga. Pertaining To over a century,each extracts associated with T. Iboga and its constituent alkaloids, which includes ibogaine, havebeen employed as medicinals (1). Precisely what tends in order to make this alkaloid regardingparticular curiosity to be able to contemporary pharmacology are generally anecdotal observationsindicating in which ibogaine possesses "anti-addictive" properties. Thus, ibogaine (6-25 mg/kg,throughout humans) continues for you to be claimed to attenuate each dependence as well aswithdrawal signs along with symptoms into a variety of abused drugs such as opiates, alcohol,nicotine and psychostimulants (2-9). Preclinical studies demonstrating which ibogaine minimizesself-administration associated with each cocaine as well as morphine, and attenuates the actual theindicators of morphine-withdrawal, are consistent using these claims [reviewed in (Popik and alsoGlick (10)]. This kind of chapter evaluations the particular pharmacological properties of ibogainealong with associated alkaloids. Since our final comprehensive review (11), a lot more than onehundred new studies about the pharmacological actions regarding ibogaine and also ibogaine-likealkaloids have got appeared. Your chemistry of ibogaine continues to be able to be reviewed byTaylor on this series (12,13).

TOP

II. HISTORICAL OVERVIEW.

Ibogaine is actually derived via Tabernanthe iboga, a new shrub indigenous for you to Central-WestAfrica. the iboga shrub, any part of the particular family Apocynaceae (order Contortae), is normallydiscovered within the undergrowth involving tropical forests (14). the roots of Tabernanthe ibogawere used inside tribal initiation rites (15,16). Even though the facts of such ceremonies vary, it hadbeen believed that iboga root enabled initiates to make experience of ancestors in the spirit world.Ibogaine has also been found in Tabernanthe crassa (17). Nineteenth century reviews via Frenchand Belgian explorers initial described the actual stimulant along with aphrodisiac results ofconsuming Gated Community Chevy Chase MD iboga root (1,16). The really first botanicaldescription of the plant, ended up being created by Baillon inside 1889 (18).

Dybovsky along with Landrin (19), also as Haller and also Heckel (20), had been the first for you toisolate the crystalline alkaloid from iboga root, which in turn these people called "ibogaine" or"ibogine". Within 1901 French pharmacologists discovered ibogaine to get an unusual kind ofexcitatory effect within animals (21-23). Phisalix (23) suggested that will ibogaine could producehallucinations according to observations of unusual behavior within dogs. The Actual alkaloid endedup being subsequently tested throughout Western clinical settings, and has been advised as astimulant for the remedy of convalescence as well as neurasthenia (24). Regardless of suchrecommendations, ibogaine in zero way enjoyed wide clinical use and ended up being neglected bysimply researchers for nearly 30 years. Throughout the 1940's Raymond-Hamet along withcoworkers published the number of papers describing the actual pharmacological propertiesinvolving ibogaine in isolated tissues and the cardiovascular system (25-32).

Lambarene, an extract with the roots with the iboga relative Tabernanthe manii, was bought fromFrance throughout the 1930's. It contained concerning 8 mg regarding ibogaine, along with ended

up being described as becoming a stimulant. Iperton, yet another ibogaine extract, had been alsoemployed as being a tonic or even stimulant (33). Ibogaine has been utilized by athletes as being aperformance enhancing drug (34). Throughout many countries, including the particular UnitedStates, ibogaine use can be prohibited, perhaps due in order to the purported hallucinogenic results(widely publicized within the late 1960's) and its look around the illicit drug market. Inside 1970, theUnited States of America food along with Drug Administration classified ibogaine as a schedule Isubstance (all non-research use forbidden).

Beginning within 1985, a new number of patents ended up being issued for the use associated withibogaine as a rapid method of interrupting addiction to narcotics (morphine as well as heroin) (3),cocaine and amphetamine (4), alcohol (5), nicotine (6) as well as poly-drug dependency syndrome(35). These patents claim an oral or perhaps rectal dose regarding ibogaine (4-25 mg/kg) interruptsyour dependence syndrome, permitting patients to be able to maintain a drug-free lifestyle withregard to a minimum of six months.

Based upon open up clinical studies, it has been claimed (36) that will ibogaine therapy resultedwithin 25% regarding patients remaining drug-free with out craving regarding six months. This teamincluded individuals who were each highly motivated to quit along with had relatively steady homeenvironments. An Additional 40-50% associated with patients had their particular addictionsinterrupted successfully, along with necessary psychotherapy. Twenty to always be able to 30% ofpatients had returned to become able to drug use inside a new month subsequent treatment.Somewhat lower success rates (10-15%) are generally cited simply by Touchette (37).

In your absence of appropriately controlled clinical studies, your efficacy of ibogaine as any possibleanti-addictive agent can't be rigorously assessed at the current time. Nonetheless, curiosity aboutibogaine as becoming a treatment method pertaining to addiction offers increased. Throughout 1985NDA International, Inc. (Staten Island, NY, USA) began any campaign to persuade your U.S.government for you to initiate managed clinical trials using ibogaine (38). at the same time, the useof ibogaine for treating opioid dependence has increased within Europe (39). In present, clinicaltrials for you to assess the safety involving ibogaine are usually underway in the College of Miamiand so are planned within New York. Clinical trials to end up being able to test the anti-addictiveefficacy regarding ibogaine are underway in The Particular Netherlands along with Panama (38,40-44). Based on Ali et al., (45), the particular U.S. food and Drug Administration and the NationalInstitute with regard to Drug Abuse features approved the utilization regarding ibogaine on therestricted schedule to end up being able to treat cocaine addiction.

TOP

III. CHEMICAL STRUCTURE AND PROPERTIES.

Figure 1.

Compound R1 R2 R3 R4

Ibogaine CH2CH3 H OCH3 H

O-Desmethylibogaine CH2CH3 H OH H

( )-Ibogamine CH2CH3 H H H

( )-Coronaridine CH2CH3 CO2CH3 H H

Tabernanthine CH2CH3 H H OCH3

O-t-Butyl-O-Desmethylibogaine CH2CH3 H OC(CH3)3 H

Although ibogaine had been first isolated along with identified within 1901, (19-21,46), theparticular composition associated with this and related alkaloids (Fig. 1) had been first establishedby simply Taylor in 1957 (47) [see in addition Taylor (12,13)]. Total synthesis via nicotinamide hasbeen reported utilizing a 13- (48) as well as 14-step (49) sequence. Your 13C NMR spectra of severaliboga alkaloids were published throughout 1976 (50). The Particular synthesis involving tritiatedibogaine has been lately reported (51,52).

Ibogaine (mol. wt. 310.44) includes a melting point of 153 in 0.01 mm Hg and a pKa regarding 8.1in 80% methylcellosolve. Your absorption maxima inside methanol tend to be 226 (log e 4.39) and296 (log e 3.93) nm. Ibogaine crystallizes from alcoholic options into small, reddish prismaticneedles; it's levorotatory [a ]D -53 (in 95% ethanol) and is soluble in ethanol, methanol,chloroform and acetone, yet insoluble in water. Ibogaine hydrochloride (freezing point 299C, [a ]D-63 (ethanol), [a ]D -49 (H2O)) can be soluble inside water, ethanol as well as methanol, isslightly soluble inside acetone along with chloroform, and is practically insoluble in ether (53).Ibogaine will be heat- as well as light-sensitive (54) and may spontaneously oxidize within solution,providing iboluteine and also ibochine (16,34). Alkaloids structurally associated to ibogaine includetabernanthine, ibogamine, iboxigaine, gabonine, iboquine, kisantine and also ibolutenine. Structuralcommonalities in between ibogaine along together with other indole alkaloid hallucinogens get alsobeen reported (55). The Particular synthesis of several ibogaine derivatives has recently beenpublished by Repke along with coworkers (56).

TOP

IV. PHARMACOKINETICS.

After parenteral administration, ibogaine continues to be identified in the variety of biologicalmaterials, which includes blood along with urine (humans) along with within the liver, kidney andmind involving laboratory animals (54,57-59). 1 hour after intraperitoneal administration, highconcentrations involving ibogaine had been current within rat liver as well as kidneys (60). RightAfter intravenous injection associated with 10 mg/kg in order to mice, maximal mind concentrations(48 g/g involving wet excess weight [~133 M]) had been achieved inside 10 sec (61).

Recently, Gallagher et al., (62) have got designed a extremely sensitive along with particular methodto quantify ibogaine inside plasma as well as tissues. This kind of approach makes use of organicextraction, derivatization along with trifluroacetic anhydride, and also detection by gasolinechromatography-mass spectrometry (GC/MS). Comparable strategies had been developed by Hearnet al., (63), Alburges et al., (64) and Ley et al., (65). Making Use Of the GC/MS method, Pearl andalso colleagues (66) reported in which 1, 5 and also 19 hours following intraperitonealadministration associated with 40 mg/kg regarding ibogaine, the whole mind ranges of ibogainewere 10, 1 and also 0.7 M within female rats and 6, 0.9 and 0.2 M throughout male rats,respectively. Hough et al., (67) studied your tissue distribution of ibogaine after i.p. and also s.c.administration in rats. 1 hour after i.p. dosing (40 mg/kg), drug amounts ranged via 106 ng/ml (~ 0.3M) within plasma to be able to 11,308 ng/g (~ 36 M) inside fat, together with significantlyhigher values after s.c. administration associated with the identical dose. Drug amounts had been10-20 fold lower 12 hrs later. These types of data indicate that will ibogaine will be subject for you toa substantial "first pass" impact right after i.p. dosing, as well as in which there exists a markedpropensity pertaining to ibogaine being deposited in adipose tissue, reflecting its lipophilicity.

Steady using its lipophilicity, ibogaine ranges throughout adipose tissue were high regarding aminimal of 12 hours following administration. Based in these data, it was suggested that a newsingle dose of ibogaine might give a long-acting, depot-like moment strategy (67).

The reported long-term effects of ibogaine (e.g. (68-70)), have led to the hypothesis this alkaloid mayalways be metabolized to an active principle with a extended half existence (71). In present, there isabsolutely no direct evidence to guide this hypothesis. Ibogaine was reported to disappear from yourrat in a price involving ~4% in the administered dose hourly along with ~ 5% with the injected doseeliminated unchanged within urine. Elimination kinetics via mind yielded any half-life associatedwith 60 min throughout rodents (60,61) along with suggest any one-compartment model. Right Afteradministration regarding ibogaine (10 mg/kg, p.o.) to rabbits, urine concentrations reached themaximum 4-5 hrs later, then decreased rapidly and disappeared after six hours (54,60). Takentogether, these data claim that ibogaine is actually extensively metabolized. Inspection involvingibogaine's composition (Fig. 1) led us in order to hypothesize which a new most likely degradationpathway is O-demethylation from C12. Based about this hypothesis, O-desmethylibogaine (alsoreferred in order to as noribogaine or 12-hydroxyibogamine), has been synthesized by Dr. C. Berthain the National Institutes associated with health inside 1994. at the same time, O-tert-buty--O-desmethylibogaine ended up being synthesized in an attempt to produce an ibogaine derivativeresistant to end up being able to O-demethylation (Fig. 1). Thus, the initial compound has beensynthesized to investigate the prospective pharmacological actions of your likely ibogainemetabolite. Your 2nd compound permitted examination in the pharmacological results of an ibogainederivative that would certainly not always be degraded through O-demethylation. The Particularsynthesis of these compounds had been described by simply Layer et al., (72).

Recent studies have indeed demonstrated that ibogaine is metabolized, as well as which O-desmethylibogaine can be detected within human plasma (73) too as inside the plasma along withbrains of ibogaine-treated rats (66). Behavioral as well as neurochemical studies throughout rodentsget proven that will O-desmethylibogaine will be pharmacologically active (discussed later).

Following an i.p. dose associated with ibogaine (40 mg/kg), Pearl et al., (66) reported brain O-desmethylibogaine concentrations associated with 20, 10 and also 0.8 M throughout female ratsas well as 13, 7 as well as 0.1 M throughout male rats, respectively, in 1, 5, and 19 hrs afteradministration. These information suggest that gender differences in pharmacological responses inorder to ibogaine might be attributed to end up being able to pharmacokinetic, instead ofpharmacodynamic, factors. Whilst the report of one human subject (73) indicated that will O-desmethylibogaine persisted inside plasma from high amounts pertaining to a minimum of 24 hoursfollowing oral ibogaine administration, it just isn't clear if this pattern is likely to be representative.

There will be evidence indicating that will the various pharmacological effects of ibogaine might endup being attributable, no less than throughout part, for you to its metabolite(s). for example, yourtremorigenic results of ibogaine dissipate far more rapidly compared to its power to attenuate theactual morphine withdrawal syndrome within rats (74). This specific obtaining indicates an activeprinciple(s) responsible for starters action might always be much more rapidly metabolizedcompared to compound(s) involved with additional actions. Alternatively, the variouspharmacological results of ibogaine may involve distinct neurotransmitter pathways (discussedlater).

TOP

V. GENERAL PHARMACOLOGICAL ACTIONS.

A. Animal Studies

1. Locomotor activity.

Ibogaine generates complex results on locomotor exercise within rodents. Any dose associated withtwenty mg/kg (i.p.) slightly elevated locomotor activity in mice (75) while Sershen et al., (76)reported that will 40 mg/kg (i.p.) decreased locomotor exercise within male mice in 1, but not 24,hours right after injection. Your same dose inhibited locomotion in female rats throughout the firsthour right after injection, whereas one week later on locomotor exercise was increased (69).

Recently, Pearl and also colleagues (66) noted gender distinctions within the results of ibogaine onlocomotor activity (40 mg/kg, i.p., 5 or 19 hours before test). in control males along with females theactual locomotor activity decreased in the program of the second hour involving observation.Ibogaine treatment in females prevented this decline in locomotor activity. Inside females, althoughnot males, ibogaine decreased locomotor exercise when offered 19 hrs prior to the test (66). YetAnother research revealed that in male rats, a new single dose associated with 40 mg/kg inhibitedlocomotor activity 4 hours following injection; a dose associated with 80 mg/kg decreased motoractivity a day following injection (77).

Rats injected with doses regarding 20-60 mg/kg regarding ibogaine displayed slower reactionoccasions in sensory along with sensory-motor exams as well as had been in addition impaired inperforming certain motor reflexes at doses involving 40-60 mg/kg. Furthermore, these rats exhibitedany marked reduction inside locomotor activity too as with emotionality from doses including 10- 40mg/kg. With higher doses (40 mg/kg), rats appeared virtually inactive (78). Throughout various otherstudies, at doses above 25 mg/kg, ibogaine produced ataxia, splayed hind limbs, outstretchedforelimbs, Straub tail as well as hyperexcitability (79).

One hour right after O-desmethylibogaine or perhaps 18-methoxy-coronaridine injection (40 mg/kg),locomotor exercise had been increased during the second hour regarding observation (66,80). Insideour studies, high doses (120 mg/kg) associated with O-desmethylibogaine along with O-t-buty--O-desmethylibogaine produced profound ataxia as well as convulsions (72). Ibogaine, O-desmethylibogaine, as well as O-t-butyl-O-desmethylibogaine, (80 mg/kg) failed to significantlyinfluence rotorod performance in mice (72).

TOP

a. Outcomes about locomotor activity induced through other drugs

Ibogaine may be discovered for you to affect the particular motor stimulant properties associatedwith amphetamine, cocaine, and also morphine within rodents (hyperlocomotion induced by simplythese drugs is assumed in order to reflect their "psychotomimetic" qualities inside man). Eventhough the final results of those studies usually are generally not uniform, throughout general, it hasbeen found that in female rats this alkaloid potentiates the actual locomotor reaction toamphetamine along with cocaine, whereas opposite effects were reported throughout male ratsalong with mice.

Sershen et al., (81) found that ibogaine (40 mg/ kg i.p., 2 or even 18 hours before amphetamine)enhanced amphetamine (1 mg/kg) - induced hypermotility within female rats. in some other studies,an amphetamine-induced rise in locomotor activity had been potentiated in female rats pretreatedwith ibogaine (40 mg/kg, i.p.) 19 hours earlier (82). Cocaine-induced hypermotility in female rats hasbeen in addition potentiated through ibogaine (83,84). Broderick et al., (85,86) reported which

ibogaine (20-40 mg/kg, i.p.) administration to be able to male rats regarding 4 days reduced cocaine(20 mg/kg) - induced hypermotility. Ibogaine (40 mg/kg, i.p.) administration in addition reducedcocaine- (25 mg/kg, s.c.) induced hypermotility inside male mice (76), a new finding in agreementwith almost all the amphetamine (1 mg/kg) - ibogaine interaction (81) in this gender along withspecies. Current data demonstrate that the outcomes of ibogaine about cocaine (20 mg/kg) -inducedhyperactivity inside female rats tend to be occasion dependent. Thus, given one h before cocaine,ibogaine and O-desmethylibogaine (40 mg/kg) inhibited cocaine-induced hyperactivity, yet whenprovided 19 h before cocaine they produced the opposite effect (80).

Ibogaine pretreatment (40 mg/kg, i.p. 19 hrs just before measurement) decreased as well as blockedyour locomotor stimulation induced simply by morphine (0.5-20 mg/kg) within rats (69,71). Ibogaineadministered 1 week (but not merely one month) prior to morphine (5 mg/kg) reduced the actualmotor stimulant results of this opiate (69). Pearl et al., (87) discovered that ibogaine (5-60 mg/kg) isa fantastic deal more potent within inhibiting morphine-induced hyperlocomotion in rats pretreatedalong with morphine with regard to numerous (1-4) days compared to non-pretreated rats. Dosesassociated with ibogaine (5-10 mg/kg) in which on your own own were inactive in drug-naive animalsattenuated morphine-induced hyperactivity in the morphine pretreated rats. the inhibitory outcomesof ibogaine about morphine-induced hyperlocomotion seem gender related, simply because ibogaineis a great deal more potent throughout female rats (66). Ibogaine-induced inhibition associated withmorphine - induced hyperlocomotion can be reversed by simply coadministration of your kappaantagonist (norbinaltorphine, 10 mg/kg) and an NMDA agonist (NMDA, 20 mg/kg). However, neithernorbinaltorphine nor NMDA by yourself blocked this motion of ibogaine (88).

O-Desmethylibogaine (10-40 mg/kg) additionally inhibited morphine-induced hyperlocomotionthroughout female rats. Nevertheless in male rats, the dose involving ten mg/kg potentiated and 40mg/kg inhibited morphine-induced hyperlocomotion (66,89).

TOP

2. Tremor.

Like the somewhat structurally associated alkaloid harmaline, ibogaine generates tremors.Throughout mice, ibogaine will be tremorigenic both when provided intracerebrally (ED50 127nmol/g brain, ~ 46 g/g using a latency in order to tremor regarding about one minute) (90), alongwith systemically (ED50 12 mg/kg, s.c.) (61). in rats, ibogaine produced fine tremors, flatteningregarding body posture, and flaccid hind limbs up to 2 hrs after administration associated with 40mg/kg (i.p.) (91). Low-amplitude whole body tremors appearing within ten min followingadministration associated with as little as ten mg/kg regarding ibogaine get additionally beenreported (92). O'Hearn et al., (93) reported in which a higher dose regarding ibogaine (100 mg/kg)produced ataxia as well as high-frequency tremor in the head along with trunk throughout rats.Ibogaine-induced tremor preferentially involves the head and upper extremity throughout rats andmice (94). Ibogaine (20 mg/kg) - induced tremors in mice were blocked more potently through CCK-8as well as ceruletide compared along along with other reference compounds, which includes prolyl-leucylglycine amide (MIF), atropine, haloperidol, biperiden, ethopropazine, trihexyphenidyl,methixene along with clonazepam (95).

Zetler et al., (61) established your tremorigenic structure-activity relationship of countless ibogaine-like compounds inside descending order of potency: tabernanthine > ibogaline > ibogaine >iboxygaine > O-desmethylibogaine. Glick et al., (96) found out that at behaviorally successful doses(2-80 mg/kg) ibogaine, desethylcoronaridine, harmaline and also tabernanthine produced tremorsregarding at least 2-3 hours. Each your R and S enantioners regarding ibogamine and coronaridine

were devoid associated with this action. the ibogaine-like alkaloids, 18-methoxycoronaridine as wellas O-desmethylibogaine had been additionally located to be able to lack tremorigenic outcomes(89,97).

The tremorigenic properties of ibogaine along with related compounds happen in order to beattributed to an action in GABAergic pathways (98-100) along with for the blockade associated withvoltage-dependent sodium channels.

TOP

3. Anxiety along with fear.

Schneider and Sigg (101) described the particular behavioral outcomes of ibogaine in cats. TheParticular authors concluded which after intravenous administration involving 2-10 mg/kg, ibogaineproduced fear-like reactions that will persisted for 10-20 minutes having a typical physicalappearance observed 1-2 hours right after injection. The Actual electroencephalographic patternobtained after ibogaine administration (2-5 mg/kg) confirmed an average arousal syndrome,resembling that observed after direct stimulation in the reticular formation. This kind of arousalsyndrome had been inhibited simply by atropine (2 mg/kg) (101). Gershon as well as Lang (102)described the results of ibogaine throughout dogs, which become more tense and also alert,interpreted as the appearance involving anxiety. Moreover, these people observed the dogsexhibited the insufficient recognition involving each his or her standard handlers and environment.

Recently, Benwell et al., (103) reported reductions throughout open up arm entries within theelevated plus-maze test when rats were tested 22 hours right after pretreatment with ibogaine (40mg/kg, i.p.). Throughout mice, ibogaine (2.5 mg/kg) exhibited anxiogenic actions, whereas a doseassociated with one mg/kg had anxiolytic effects (104). These are perhaps the most compellingpreclinical data which ibogaine may influence anxiety levels since anxiolytic agents (e.g.benzodiazepines) increase open arm entries within this test.

TOP

4. Outcomes on self-administration associated with additional drugs.

Ibogaine (40 mg/kg, i.p.) inhibits the actual self-administration associated with cocaine in rodents.Cappendijk and Dzoljic (105) trained male Wistar rats to always be able to intravenously self-administer cocaine; a single dose involving ibogaine (40 mg/kg) decreased cocaine consumption by40-60% with regard to a quantity of days, as well as repeated therapy along with ibogaine in one-week intervals decreased cocaine self-administration simply by 60-80%. This kind of decrease wasmaintained pertaining to numerous weeks. Comparable results were seen in mice that will designeda choice with regard to cocaine in the drinking water. Thus, ibogaine administration (two weeksfollowing the beginning of your choice period, 2 doses regarding 40 mg/kg, six hrs apart) diminishedcocaine preference pertaining to five days (70). According to Vocci and also London (106), someinvestigators have failed to replicate ibogaine's effect about cocaine self-administration in the rat(107) and rhesus monkey (108). also Dworkin et al., (109) reported in which neither 40 mg/kginvolving ibogaine provided 60 min prior towards the session, nor 80 mg/kg given round-the-clockahead associated with the session, suppressed responding maintained by intravenous cocaineinfusions. in this study, cocaine self-administration has been inhibited by simply pretreatment withibogaine (80 mg/kg) both 60 as well as 90 min prior towards the session (109). However, since thisdose associated with ibogaine reduced scheduled meals intake, these latter outcomes of ibogaineabout cocaine self-administration appear to be unspecific.

Glick et al., (96) demonstrated that will ibogaine along with several iboga alkaloids (tabernanthine,R- and S-coronaridine, R- along with S- ibogamine, desethylcoronaridine, and harmaline) reducedcocaine self-administration in rats inside a dose-related fashion (2.5-80 mg/kg). With Regard To arange of alkaloids, these effects were seen the afternoon after injection. O-Desmethylibogaine (40mg/kg) (89) and also 18-methoxycoronaridine (97) were in addition reported for you to inhibitcocaine self-administration.

Ibogaine dose dependently (2.5-40 mg/kg) reduced intravenous morphine self-administrationthroughout female Sprague-Dawley rats instantly right after injection too as on the overnight (68). Incertain animals, a new reduced morphine consumption has been observed for numerous days; otherrats required a range of doses associated with ibogaine to be able to achieve a prolonged reduction.similar effects were demonstrated regarding additional ibogaine-like alkaloids which includes O-desmethylibogaine (89), tabernanthine, R- as well as S-coronaridine, R- and S- ibogamine,desethylcoronaridine, harmaline (96) as well as 18-methoxycoronaridine (97). However, informationvia yet another study revealed somewhat various results. Thus, Dworkin et al., (109) found out thatibogaine (40 or perhaps 80 mg/kg) diminished heroin self-administration within male Fisher ratsmerely around the day it absolutely was administered. Moreover, the same research said thatibogaine treatment resulted inside a 97% decrease in responding for a food reinforcement schedule,suggesting that it is effects upon heroin self-administration had been unspecific.

Ibogaine-induced inhibition regarding morphine self-administration has been found being reversedby simply sequential administration of your kappa antagonist (norbinaltorphine, 10 mg/kg) plus anNMDA agonist (NMDA, twenty mg/kg). Neither norbinaltorphine nor NMDA on your own own wereeffective on this respect (88).

Ibogaine (10-60 mg/kg) reduced alcohol consumption throughout alcohol-preferring Fawn Hoodedrats, without affecting both blood alcohol concentrations or perhaps food intake (110,111). Yourauthors concluded which the metabolite could possibly be involved, simply because ibogaine hasbeen successful in this measure when administered intraperitoneally as well as intragastrically, butnot subcutaneously (112). The current research demonstrated an attenuation of drinking from theibogaine congener, 18-methoxycoronaridine in rats (113).

TOP

5. Outcomes upon drug dependence.

Repeated administration of ibogaine (10 or perhaps 40 mg/kg) didn't generate dependence insiderats as measured utilizing the actual primary Bodily Dependence test (114).

In morphine-dependent rats, the particular opioid antagonist naloxone induces a withdrawalsyndrome, characterized (in rats) by elevated rearing, digging, jumping, salivation as well as "wet-dog" head shaking. Ibogaine dose-dependently reduced how often regarding many associated withthese withdrawal signs (jumping, rearing, digging, head hiding, chewing, teeth chattering, writhing,penile licking) right after both intracerebroventricular (4-16 g) (115) as well as i.p. administration(40 as well as 80 mg/kg) (74,116). However, these effects couldn't be replicated inside additionalstudies in both rats (39,117) or mice (118). From least the second failure to become able to replicatemay be attributed to the fact that inside the Frances et al., (118) study, ibogaine had beenadministered to animals which designed a full withdrawal syndrome. Throughout morphine-dependent monkeys, ibogaine (2 and also 8 mg/kg, s.c.) partially suppressed your total variety ofwithdrawal signs (114). Our studies (72,119) demonstrate that will ibogaine inhibits the morphinewithdrawal syndrome throughout mice in a dose-related fashion. This effect was reversed by simply

combining ibogaine remedy using glycine. Structure-activity studies said that amongst variousibogaine-like compounds (including O-desmethylibogaine and also O-t-butyl-O-desmethylibogaine),simply ibogaine inhibited your intensity involving morphine withdrawal (72). Each the particularability of glycine to become able to inhibit this impact regarding ibogaine and furthermore thefailure of additional ibogaine derivatives in order to potently inhibit the actual binding ofnoncompetitive NMDA antagonists (e.g., [3H]-N-[1-(2-thienyl)cyclo-hexyl]-3,4-pi... (TCP) and [3H]-MK-801) shows that the actual NMDA antagonist actions associated with ibogaine are usuallyresponsible for its anti-withdrawal effects. This particular hypothesis is supported from theobservation in which although O-desmethylibogaine and also O-t-butyl-O-desmethylibogaine hadhigher affinities regarding kappa opioid receptors compared to ibogaine did, only ibogaine exhibitedan important affinity with regard to NMDA receptors.

TOP

6. Pain and also analgesia.

Ibogaine didn't mimic the actual analgesic action of morphine in both the actual tail flick (1-40mg/kg, i.p.) or perhaps hot plate (up to always be able to twenty mg/kg, i.p.) tests, though itexhibited analgesic activity in the phenylquinone writhing test (ED50 9.7 mg/kg) (114,120,121).Ibogaine did not exhibit antinociceptive exercise when offered twice a day with regard to 4 times(122). Ibogaine either increased (120,123) or even failed to affect (114,121) morphine analgesiawithin the tail flick test. Similarly, it did not influence analgesia produced simply by either any kappaopioid agonist (U-50,488H) or even a delta opioid agonist [D-Pen2,D-Pen5]enkephalin (DPDPE)(121). Ibogaine may be reported to lower analgesia throughout rats when offered 19 hours justbefore morphine (123), however another statement signifies ibogaine isn't efficient when offered 4-24 hours ahead of morphine administration throughout mice (121). Throughout addition, Cao alongwith Bhargava (122) demonstrated that ibogaine (40-80 mg/kg) inhibited the development ofanalgesia to become able to mu, although not kappa or perhaps delta, agonists within mice.

O-Desmethylibogaine (40 mg/kg) potentiated morphine-induced analgesia inside rats (123) and mice(121). This kind of effect ended up being no longer apparent 19 hours after its administration (123).The Particular potentiation involving morphine-induced analgesia could be attributed to therelatively high affinity involving O-desmethylibogaine with opioid mu (Ki 2.66 0.62 M) and alsokappa (Ki 0.96 0.08 M) receptors (124). However, this interpretation appears unlikely simplybecause O-desmethylibogaine pretreatment failed to influence both kappa - or even delta - opioidagonist - induced antinociception (121).

Ibogaine (10-40 mg/kg) totally blocked the actual antinociceptive effect involving (-)-epibatidine inrodents, but was ineffective when offered in a dose regarding 40 mg/kg 24 h just before epibatidine.These information declare that it was an effect of ibogaine rather than that relating to its putative,long-lasting metabolite (125). This specific blockade in the antinociceptive impact of epibatidine justisn't surprising, simply because epibatidine-induced analgesia will be mediated by a mechanismfundamentally various from those of your opioids.

TOP

7. Aggression.

Compared along along with other psychoactive compounds (e.g. psilocybin, JB-336, and alsobufotenine), ibogaine (10 mg/kg) had a negligible impact on the aggressiveness regarding isolatedmice and also muricidal behavior throughout rats (126).

TOP

8. Interoceptive properties.

Animals can easily learn to "recognize" parallels amongst drugs. Such discriminative (interoceptive)properties could suggest the comparable mechanism regarding action definitely not related for theconstruction of your compound.

No generalization among ibogaine along with serotonergic ligands (e.g. fenfluramine, N-(--trifluoromethylphenyl)piperazine [TFMPP], 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopr... [DOI],methyl-enedioxymethamphetamine [MDMA], quipazine as well as LSD) had been seen in drug-discrimination paradigms (127,128). However, Palumbo as well as Winter (129) do observe thegeneralization among ibogaine (15-20 mg/kg) as well as dimethoxymethylamphetamine [DOM] (0.6mg/kg), as well as among ibogaine along with LSD (0.1 mg/kg) in the two-lever discrimination task.Since pizotyline (BC-105) blocked DOM-appropriate and also LSD-appropriate responses, aninvolvement associated with 5-HT2 or even 5-HT1 receptors inside the stimulus properties ofibogaine had been suggested. Similarly, zero generalization in between ibogaine and CGS 10476B (adopamine release-inhibiting agent) was discovered in the drug-discrimination paradigm (127).

In contrast, ibogaine substituted as a possible interoceptive cue inside mice educated to recognizeMK-801 (dizocilpine) (119), although not in order to [(+)-HA-966] (a reduced efficacy partial agonistof the glycine site in the NMDA receptor) (130) inside a T-maze drug discrimination paradigm.

Helsley as well as colleagues (131) studied the actual interoceptive cue produced by simply ibogaineinside male Fisher rats. The Actual occasion span of your ibogaine (10 mg/kg) cue says a newmaximum associated with ibogaine-appropriate responses had been observed with a 60 minpretreatment time, and, in which at the pretreatment duration of eight hours, zero ibogaine-likeresponses were observed. These kinds of findings, together along with observation that O-desmethylibogaine substituted merely partially towards the ibogaine cue, declare that yoursubjective outcomes of ibogaine aren't due in order to this putative metabolite. Your same studyhowever, revealed that harmaline completely substituted as an ibogaine cue (131). This kind of lateron finding indicates that animals could recognize the particular tremorigenic outcomes of ibogaine.

TOP

9. Reinforcing effects.

Ibogaine will not appear to possess satisfying or even aversive effects as measured inside theconditioned location preference/aversion test (132), a new preclinical procedure that may predictabuse potential throughout humans. Nonetheless, exactly the actual same authors reported thatibogaine (40 mg/kg) might attenuate the particular acquisition, although not expression of morphinealong with amphetamine place-preference throughout male rats (77,132,133). This particular dose ofibogaine failed to interfere with just about all the acquisition regarding conditioned location aversioninduced by simply both naloxone or lithium chloride (132). Ibogaine (40 mg/kg, 22 hrs prior to thetest) attenuated the actual institution involving lithium- as well as morphine-induced conditionedtaste aversion (134). These results suggest a specific action involving ibogaine on the neurochemicalalong with behavioral (both reinforcing as well as aversive) actions involving morphine as opposed toupon opioid system(s), as the reinforcing results of naloxone were unaffected. Throughout assistanceto these findings, it has been reported in which ibogaine (20 or perhaps 40 mg/kg, 24 h prior for youto the test) neither decreased the choice for a sweet answer nor attenuated conditioned preferencefor any flavor formerly associated using sweet taste (135).

TOP

10. Results upon studying as well as memory.

At any dose utilized inside the majority associated with contemporary behavioral studies insiderodents (40 mg/kg), ibogaine has been found to end up being able to attenuate the acquisition ofspatial memory, maybe thanks for you to reductions inside locomotor exercise and in detectionregarding sensory details (78). However, in much lower doses (0.25 - 2.5 mg/kg), ibogaine also as O-desmethylibogaine (but not necessarily O-t-butyl-O-desmethylibogaine) facilitated spatial memoryretrieval (136). Utilizing a spatial memory task, Helsley et al., (92) discovered that: 1) two dosesinvolving ibogaine (50 mg/kg, spaced by simply eight hours) decreased your response rate, howeverdid not affect acquisition rate; 2) ibogaine, even in the highest doses associated with 30 and 46mg/kg given 20 min ahead regarding the mastering trial didn't affect job acquisition; 3) 30 mg/kgassociated with ibogaine administered just following your learning trial facilitated the consolidationregarding memory trace.

TOP

11. Cardiovascular actions.

Gershon as well as Lang (102) found that ibogaine produced the rise in blood pressure and elevatedheartrate in conscious dogs. These kind of effects were blocked simply by atropine (137). However,inside anesthetized dogs, ibogaine produced the fall throughout blood pressure and reducedheartbeat reduction, leading the authors to propose an interaction in between anaesthesia and thecardiovascular outcomes of ibogaine (102). Schneider along with Rinehart (137) postulated anycentrally mediated stimulatory impact associated with ibogaine. Ibogaine furthermore potentiatedthe pressor reaction to each adrenaline and also noradrenaline. more recently, Hajo-Tello et al.,(138) discovered that tabernanthine (an alkaloid closely associated for you to ibogaine) induced anadverse inotropic impact throughout electrically stimulated myocardial tissue along with a negativechronotropic effect in the perfused rat heart. Tabernanthine in addition produced bradycardia aswell as hypotension throughout anesthetized rats along with dogs (139). Binienda et al. (140)reported that will ibogaine (50 mg/kg) reduced heart rate in rats instantly after injection; thisreduction persisted as significantly as 90 minutes following injection.

TOP

B. Human Studies.

Numerous psychotropic actions regarding ibogaine happen to end up being able to be reported.These kinds of actions seem to depend upon each dose as well as setting. Throughout addition, thepsychoactive results of iboga extracts (which are likely to contain additional alkaloids and thus aretypically taken inside a ritualistic setting) could differ via those of ibogaine. Thus, users with thecrude extract associated with Tabernanthe iboga taken inside sufficiently higher doses get reportedfantastic visions, feelings regarding excitement, drunkenness, mental confusion as well ashallucinations when (101). The Actual total extract regarding iboga shrub is certainly a new centralstimulant, as well as in higher doses may result in convulsions, paralysis last although not leastrespiratory arrest. The Particular psychotropic actions involving the flower extract include visualsensations; objects tend to be seen being flanked by specters as well as rainbows. Inside high dosesit might create auditory, olfactory as well as taste synesthesias. The Particular frame involving mindcontinues to become able to be reported to vary from profound fear for you to frank euphoria (141).

When offered orally, both ibogaine and the total iboga extract elicits subjective reactions that willlast for approximately six hours. fifty percent associated with topics tend to be reported to encounterdizziness, incoordination, nausea, as well as vomiting (7,33,142). Typically, the actual drug produceda situation involving drowsiness in which subjects didn't need to move, open up their eyes, as well asshow up at to the environment. Many topics had been light-sensitive, and covered their eyes as wellas asked that the lights be turned off. Sounds as well as noises were disturbing. Ibogalin (0.1-1.2mg/kg, p.o.), an alkaloid closely associated to ibogaine and a constituent of the total iboga extract,failed to create psychotomimetic outcomes within humans (143). Ibogalin additionally differs fromibogaine inside pharmacokinetics and tremorigenic activity (90).

The psychoactive properties of ibogaine and related compounds had been studied through Naranjo(33,142) who reported in which patients described the psychic state produced through ibogaine (~300 mg) as just like a fantasy state with out loss involving consciousness. Ibogaine-induced fantasies[often described like a "movie run with substantial speed" or even "slide show" (7)] were reported asrich throughout archetypal contents, involving animals and/or the niche with or even with out someother individuals. These kind of fantasies had been an easy task to manipulate through both thethemes and additionally the psychotherapist (33,142). at higher doses, ibogaine appears to be ableto create visual along using other hallucinations associated using severe anxiety as well asapprehension (101,144,145).

TOP

VI. LETHALITY AND NEUROTOXIC EFFECTS.

The LD50 associated with ibogaine has beenestablished within guinea pig (82 mg/kg, i.p.) and rat(327 mg/kg, intragastrically as well as 145 mg/kg,i.p.) (60,146).

No significant pathological modifications in rat liver,kidney, heart along with brain subsequent chronicibogaine remedy (10 mg/kg, regarding thirty days orperhaps 40 mg/kg, for 12 days, i.p.) had been

reported (60). Sanchez-Ramos and also Mash (42) discovered absolutely no proof of gross pathologyinside African green monkeys provided ibogaine in doses associated with 5-25 mg/kg, p.o. withregard to 4 consecutive days.

However, O'Hearn et al., (147,148) and O'Hearn and Molliver, (93) reported that will repeatedadministration regarding ibogaine (100 mg/kg, i.p.) for you to rats caused your degeneration of yoursubset associated with Purkinje cells inside the cerebellar vermis. This particular degenerationended up being accompanied by a loss associated with microtubule-associated protein two (MAP-2)along with calbindin. Argyrophilic degeneration, astrocytosis and microgliosis were furthermoreobserved. the damage seemed to be dependent on the existence associated with an intact inferiorolivary nucleus (149). Ibogaine-induced cerebellar toxicity appear to be independent in its actionfrom NMDA receptors, because neither MK-801 nor phencyclidine create the identical patterninvolving degeneration (150). the neurotoxic results of substantial doses associated with ibogainewere confirmed in rats, but not mice, by simply Scallet et al., (151,152) as well as Molinari et al.,(153), who, additionally discovered that the actual "typical" dose regarding 40 mg/kg failed togenerate significant injury to female rat cerebellum. the not enough neurotoxicity after lower,

behaviorally active doses associated with ibogaine has been additionally demonstrated simply byshowing which chronic administration (60 days) involving 10 mg/kg regarding ibogaine producedsimply no change in the quantity of Purkinje cerebellar cells (154).

In spite of these findings, examination involving cellular markers which tend to become moresensitive toneurotoxic agents as compared to gross histology shows that ibogaine administrationcould produce significant alternation in a excellent many other mind structures. Thus, O'Callaghanet al., (155,156) reviewed your outcomes of acute and chronic administration regarding ibogaineupon glial fibrillary acidic protein (GFAP) levels. Acutely, ibogaine elevated GFAP in both sexes;whereas chronic administration (14 days) produced raises simply throughout females. Ibogaine -induced changes in GFAP had been dose-related, and, contrary to other studies, observed insidesome other mind structures such as hippocampus, olfactory bulb, brain stem and also striatum.Inside addition, these authors reported that will throughout females treated chronically usingibogaine, severe hippocampal damage ended up being existing as measured by simply increaseswithin the cytoskeletal proteins neurofilament 68 (NF-68) along with beta-tubulin. These types oflatter markers indicate the damage-induced sprouting response (156). Ibogaine administration inaddition produced an increase in c-fos immunostaining in many mind aspects of mice along withrats; the consequences within rats were observed in all cortical layers although in mice yourresponse has been restricted to cortical layer 2 (152). Human SK-N-SH neuroblastoma cells culturedwithin the existence of 3-30 M ibogaine (but not O-desmethylibogaine or perhaps 18-methoxycoronaridine) demonstrated concentration- along with time-dependent morphologicalchanges characterized through the loss involving processes, cell rounding, detachment and alsoultimately cell death (157). Comparable results were observed using primary cultures associatedwith rat cerebellar granulae cells. Since within this study merely alkaloids that had marked affinityat sigma2 websites were neurotoxic, Vilner et al., (157) proposed that sigma2 websites might beimplicated in the neurotoxicity of ibogaine. the neurotoxic results of ibogaine happen in order to benot too long ago reviewed by Vocci and London (106).

Acute therapy with the ibogaine-like alkaloid, 18-methoxycoronaridine (100 mg/kg) failed to producegross pathological changes inside the cerebellum (97). Within contrast, an additional indole alkaloid,harmaline, produced ibogaine-like degeneration involving Purkinje cells inside the cerebellar vermis(93).

It may be reported that multiple doses of your non-NMDA antagonist (GYKI 52466) resulted inside asubstantially higher loss involving Purkinje cells along with microglial activation in comparison foryou to ibogaine (50-100 mg/kg) alone (158). Upon one other hand, the actual noncompetitive NMDAantagonist MK-801 (1 mg/kg) markedly attenuated the amount of Purkinje cell loss caused byibogaine (158). This specific later on obtaining strongly sports ths notion in which losing cerebellarPurkinje cells produced by ibogaine is unrelated to be able to its NMDA antagonist properties (159).in fact, ibogaine could furthermore exhibit neuroprotective properties, reducing glutamate-inducedneurotoxicity within primary cultures regarding cerebellar granule cell neurons with an EC50regarding 4-5 M (119). These neuroprotective outcomes of ibogaine have got lately been patentedthrough Olney (160). Constant having its properties as any possible NMDA antagonist, ibogaineinhibited NMDA - induced lethality inside mice in the dose-dependent method (161), as well asprotected mice through maximal electroshock seizures (ED50 ~ 31 mg/kg) (162).

Phase I toxicity studies throughout drug-addicted people are in progress at the university of Miami(42,163).

TOP

VII. EFFECTS ON SPECIFIC NEUROTRANSMITTER SYSTEMS

A. Ibogaine Outcomes about Dopaminergic Systems.

Ibogaine (at concentrations 100 M) doesn't affect radioligand binding for you to dopaminereceptors (D1, D2, D3, D4) (164-166). The Particular affinity involving ibogaine regarding dopaminetransporters as measured by simply inhibition involving [3H]WIN 35,248, [125I]RTI-121 or[125I]RTI-55 binding had been ~ 1.5 - 4 M (73,76,166,167). However, within an additional study,ibogaine did not affect binding involving [3H]GBR-12935, the ligand that will furthermore appearsfor you to label dopamine transporters (85). Ibogaine inhibited [3H]dopamine uptake in porcinekidney cells transfected together with dopamine transporter using a Ki ~86 M (168).

The throughout vivo along with ex vivo outcomes of ibogaine on dopamine metabolism throughoutmesolimbic places with the rodent brain (striatum, nucleus accumbens) tend to be controversial andalso highly inconsistent. Throughout an make an effort to reconcile numerous contradictory findings,one could note the following.

Dopamine concentrations tend to be reduced and also dopamine metabolites dihydroxyphenyl-aceticacid (DOPAC) as well as homovanilic acid (HVA) tend to be elevated by ibogaine under certainexperimental conditions. for example, when either measurements are usually taken shortly (withintwo h) after ibogaine administration or perhaps when relatively substantial concentrations ( 100M) are employed (69,71,76,81,169-173). Reductions inside extracellular dopamine concentrationshad been furthermore observed right after administration of the number of ibogaine derivatives,including O-desmethylibogaine (89) as well as 18-methoxycoronaridine (97).

When dopamine will be measured in longer durations right after ibogaine administration (e.g., up tothe week) or perhaps reduced concentrations (e.g., 10 M) are usually applied, brainconcentrations appear unchanged along with metabolite concentrations are usually decreased(69,71,76,81,82,169,170,172).

The increased ranges regarding extracellular dopamine metabolites collectively together withdecreased or perhaps unchanged levels regarding dopamine suggests that ibogaine increasesdopamine turnover shortly after administration. This particular may end up being adopted with areduction in turnover that will could persist for the while after ibogaine administration. French etal., (91) demonstrated that will doses involving ibogaine (~ 1.5 mg/kg, i.v.), lower when incomparison to a "typical" dose of 40-80 mg/kg, markedly excited dopaminergic neurons inside theventral tegmental region of the rat.

TOP

1. Dopaminergic effects: Pharmacological Specificity.

Administration of the kappa antagonist (norbinaltorphimine, ten mg/kg) and NMDA (10 mg/kg)(either jointly or perhaps individually) reversed ibogaine (40 mg/kg) induced decreases in striataldopamine as well as raises throughout dopamine metabolites (88). Similarly, Reid et al., (172)observed that the reduction in dopamine ranges produced by ibogaine (100 M ) had beenreversed through either naloxone (1 M) as well as norbinaltorphimine (1-10 M). However,functionally opposite outcomes had been observed by Sershen et al., (174,175) which reported thatthe ability of the kappa opioid agonist (U-62066) to end up being able to inhibit electrical- orcocaine-induced [3H]dopamine release coming from mouse striatum was attenuated simply bypretreatment involving mice together with ibogaine (40 mg/kg, i.p., 2 hours prior; or 2 x 40 mg/kg, 6

hours apart, killed 18 hours later) (174,175).

Ibogaine-induced dopamine launch in the isolated mouse striatum may be studied through Harsinget al., (176). Ibogaine increased basal tritium outflow ([3H]dopamine (DA) along with [3H]DOPAC),however ended up being without having impact upon electrically stimulated tritium overflow. Thisspecific dopamine releasing effect was: a) reduced through the dopamine uptake inhibitors cocaineas well as nomifensine, b) unaltered through omission regarding Ca++ from the perfusion buffer, c)tetrodotoxin insensitive, d) unaffected through an agonist (quinpirole) or even an antagonist(sulpiride) with the D2 dopamine receptor, as well as e) unaffected by pretreatment using reserpine.Throughout this study, ibogaine didn't affect dopamine uptake, whereas Reid et al., (172) found thatboth ibogaine as well as harmaline (10 M-1 mM) inhibited it. Since mentioned above, ibogainecontinues to end up being able to be reported in order to inhibit radioligand binding for thedopamine transporter together with relatively high affinity.

Sershen et al., (177) reported an involvement regarding serotonin receptors inside the regulation ofdopamine launch through ibogaine. Thus, administration regarding ibogaine blocked the ability ofthe 5HT1B agonist (CGS-12066A [10 M]) in order to improve [3H]dopamine increase in striatalslices. Throughout some other studies, a concentration regarding ibogaine (1 M) that was without impact in dopamine efflux inhibited each NMDA (25 M) and ( )pentazocine (100 nM) -induced dopamine release in striatal slices (178).

There are usually couple of studies in the outcomes of ibogaine-like alkaloids about dopaminemetabolism. Such As ibogaine, O-desmethylibogaine acutely decreases dopamine launch within therat nucleus accumbens and also striatum (89). Administration in the R- entantiomers associated withcoronaridine along with ibogamine decreased dopamine levels throughout both nucleus accumbensand also striatum, whereas the S-enantiomers produced zero significant alterations in dopaminelevels either in region (96).

In an make an effort to reconcile several conflicting findings, Staley et al., (167) proposed thatibogaine might market redistribution of intraneuronal dopamine through vesicular for you tocytoplasmic pools. Ibogaine displays micromolar affinity for vesicular monoamine transporterslabeled using [125I]-tetrabenazine (167); these sites are really important for that translocationinvolving dopamine directly into synaptic vesicles. the inhibitory effect of ibogaine in vesicularmonoamine transporters could result in redistribution involving dopamine in the cytoplasm. Beneathsuch conditions, rapid metabolic rate of dopamine by monoamine oxidase would account for thereduction in tissue dopamine content material as well as the parallel boost in its metabolites.

Multiple transmitter techniques have been proven to modulate dopaminergic function inside thecentral nervous system. because ibogaine can easily interact along with many of those systems,which includes kappa opioid receptors, NMDA receptors, serotonin receptors, and also dopaminetransporters, it is not shocking this alkaloid can create complex (and sometimes apparently opposite)outcomes on dopaminergic function. Thus, the particular outcomes of ibogaine on dopaminergicoperate described in this section most likely reflect the actual dose (or concentration) involvingalkaloid, preparation employed (e.g., slice versus intact animal), and also mind region studied.

TOP

2. Ibogaine alters the actual results of abused drugs on dopaminergic systems.

In general, ibogaine attenuates your increases within mesolimbic dopamine produced by drugs (e.g,nicotine, morphine) that seem to behave preferentially with dopaminergic cell bodies. Within the

situation of drugs in which act in terminal regions (e.g., cocaine and also amphetamine), a newgender distinction has been observed. in female rats, ibogaine enhances stimulant-induced raisesthroughout dopamine concentrations, whereas it decreases the actual outcomes of these stimulantsin male rats as well as mice.

Neurochemical studies were performed in male mice provided a pair of doses associated withibogaine (40 mg/kg, i.p., 18 hrs apart) followed by amphetamine (5 mg/kg) administered two hoursafter the second dose of ibogaine (81). Striatal ranges involving dopamine as well as dopaminemetabolites [DOPAC, HVA and also 3-methoxytyramine (3-MT)] measured one hour followingamphetamine were decreased in mice that will received ibogaine compared to saline-pretreated,amphetamine-treated controls. In Comparison for you to controls, amounts of DOPAC as well as HVAhad been decreased in the amphetamine along with ibogaine groups, and further decreased withinthe team that will received ibogaine along with amphetamine. However, inside female rats,amphetamine-induced raises inside extracellular dopamine concentrations inside each your striatumand furthermore the nucleus accumbens had been further potentiated by ibogaine (40 mg/kg, i.p., 19hours preceding amphetamine) (82). Similarly, Glick et al., (169) found that ibogaine potentiatedamphetamine-induced increases throughout extracellular dopamine concentrations in female ratnucleus accumbens as well as striatum. Inside this study, however, no impact regarding ibogaineended up being seen about amphetamine-induced decreases throughout extracellular concentrationsregarding dopamine metabolites. Similarly, ibogaine potentiated cocaine-induced raises throughoutextracellular dopamine ranges within striatum as well as nucleus accumbens associated with femalerats (84). However, quite opposite data were obtained by simply Broderick et al., (85,86) whichanalyzed Gated House Chevy Chase MD dopamine launch within male rats making use ofsemiderivative inside vivo voltametry. Within these experiments, ibogaine (40 mg/kg i.p. givenregarding 4 days) reduced the boost in dopamine release coming from nucleus accumbens inducedby simply cocaine (20-40 mg/kg, s.c.). A New presynaptic mechanism for these actions ended upbeing suggested. An inhibitory effect of ibogaine about amphetamine metabolic process may beproposed (179), simply because amphetamine amounts were higher following ibogaineadministration in female rats. However, ibogaine administration had no effect upon mind cocaineranges (169).

Ibogaine (40 mg/kg, i.p. in rats) offered 19 hrs prior to morphine (5 mg/kg) prevented the rise inextracellular dopamine concentration within the striatum, prefrontal cortex along with nucleusaccumbens typically observed throughout rats (71,83). However, in the ibogaine as well as morphinegroup, the particular ranges involving dopamine metabolites were elevated (as has been observedwithin the morphine group), suggesting in which ibogaine failed to stop morphine via activatingdopamine neurons. The Actual authors claim that ibogaine therapy might alter the propertiesassociated with dopaminergic neurons inside this kind of method that dopamine launch is actuallyunaffected beneath normal conditions, but altered when stimulated (in this case, by simplymorphine). Nineteen hrs after placebo as well as ibogaine (10 mg/kg, i.p.), female rats respondedsimilarly along with elevated dopamine launch inside nucleus accumbens subsequent a morphinechallenge (180). However, in rats that will received a pair of doses associated with morphine in yourcourse of two times preceding the actual experiment, ibogaine pretreatment had inhibitory resultsabout dopamine reaction into a morphine challenge. Any pharmacokinetic explanation for youroutcomes of ibogaine on morphine-induced actions will be unlikely, since ibogaine (40 mg/kg, i.p. 19hours prior to measurement) failed to modify brain levels of morphine (10 mg/kg) in rats (71).

Benwell et al., (103) reported that will ibogaine (given 22 hrs prior to nicotine) attenuated the boostin dopamine overflow within the nucleus accumbens evoked by nicotine administration. similarresults had been demonstrated, when ibogaine was administered 19 hrs just before nicotine infusion(181).

TOP

B. Opioid Systems

At concentrations regarding up to one hundred M, ibogaine has been reported never to affect[3H]carfentanil or even [3H]enkephalin binding indicating this alkaloid will not affect mu as well asdelta opioid receptors (124,165). Within contrast, Pearl et al., (124) along with Sweetnam et al.,(166) demonstrated which ibogaine inhibited radioligand binding in order to mu opioid receptorstogether with Ki values ~ 11-20 M. Ex vivo studies demonstrated which ibogaine and also O-desmethylibogaine enhanced the particular inhibition of adenylyl cyclase activity by a maximallysuccessful concentration of morphine in the rat frontal cortex, midbrain and striartum (182). Thisspecific later on impact isn't likely mediated through a new immediate action at opioid receptorsbecause it was observed in maximally efficient concentration involving morphine.

Ibogaine inhibits (Ki ~2-4 M) [3H]U-69593 binding for you to kappa opioid receptors(56,72,124,165). This particular binding can be reversible, suggesting that the long-term outcomesof ibogaine can't be attributed to an irreversible impact only from that site. Recently, Codd (183)demonstrated that will ibogaine inhibits binding in order to sites labeled by [3H]naloxonecharacterized with a two-site model, with Ki values associated with 130 nM as well as 4 M.

O-Desmethylibogaine were built using a higher affinity compared to ibogaine for most of theparticular opioid receptors studied: kappa Ki ~ one M, mu Ki ~ 2.7 M and also delta Ki ~ 24.7M (124) (a recent research confirmed higher affinity involving O-desmethylibogaine at the mureceptor; Ki ~ 160 nM (184)). Our perform (72) demonstrated that O-desmethylibogaine were builttogether with a 10- in order to 100-fold higher affinity for kappa receptors compared to become ableto ibogaine. The Actual magnitude associated with this potency difference has been species-specific(e.g., inside rats: IC50 ~ 0.3 M with regard to O-desmethylibogaine as well as IC50 ~30 M foribogaine). The Particular same research demonstrated a new reasonable affinity associated with O---butyl-O-desmethylibogaine with regard to kappa receptors (IC50 ~17 M in rat forebrain)suggesting that if any 1 of ibogaine's in vivo actions are produced with kappa receptors, then O---butyl-O-desmethylibogaine would be active. Inside this respect, O-t-butyl-O-desmethylibogaine didnot influence the morphine withdrawal syndrome (72) in doses comparable in order to ibogaine.

TOP

C. Serotonergic Systems.

Ibogaine (at concentrations approximately one M) had no impact upon [3H]serotonin binding(185) along with concentrations associated with up to 3.5 M had zero impact in [3H]LSD binding(186). A Lot More latest studies using serotonin subtype selective ligands are discrepant. Deecher etal., (165) reported that will ibogaine didn't displace ligands acting at 5-HT1a, 5-HT1b, 5-HT1c, 5-HT1d, 5-HT2, or perhaps 5-HT3 receptors. However, Repke et al., (56) reported which ibogaineinhibited binding of 5-HT1a, 5-HT2a, or even 5-HT3 ligands together with lower affinity (Ki values:>100, 12.5 as well as >100 M, respectively) along with Sweetnam et al., (166) reported IC50values regarding ~ 4 M to inhibit radioligand binding to end up being able to both 5-HT2, as wellas 5-HT3 receptors.

Despite these discrepancies, each ex vivo as well as in vivo studies suggest that ibogaine could affectserotonergic transmission. Ex vivo studies indicate that will ibogaine as well as O-desmethylibogaineenhance the particular inhibitory outcomes of serotonin on adenylyl cyclase activity inside rathippocampus (182). Broderick et al., (86) reported that ibogaine (40 mg/kg, i.p. regarding 4 days)

elevated 5-HT concentrations inside rat nucleus accumbens. Constant with this finding, Ali et al.,(171) demonstrated that ibogaine elevated 5-HT ranges inside striatum. Sershen et al., (76) reportedwhich ibogaine (40-50 mg/kg) decreased levels involving the serotonin metabolite 5-hydrox--indoleacetic acid [5-HIAA] inside mouse frontal cortex, hippocampus and also olfactory tubercle 2as well as a day after injection. Ibogaine also decreased 5-HIAA levels throughout rat nucleusaccumbens and striatum (103,171), however elevated 5-HIAA and decreased 5-HT (lasting no lessthan 7 days) inside medial prefrontal cortex (103). Lengthy and Lerrin (187) demonstrated whichibogaine is really a reversible inhibitor with the active transport involving serotonin into bloodplatelets, a locating supported by a current observation which ibogaine inhibited serotonintransporters (in any porcine kidney cell line) using a Ki ~ 10 M (168).

Sershen et al., (177) demonstrated which ibogaine inhibited your ability of the 5-HT1b agonist (CGS-12066A) in order to boost stimulation-evoked [3H]dopamine release through both rat and alsomouse striatal slices. Additionally, ibogaine increased your ability of a 5-HT3 agonist(phenylbiguanide) in order to enhance stimulation-evoked [3H]dopamine launch in the mousestriatal slice (174). in these studies, ibogaine (40 mg/kg, i.p.) has been administered two hours justbefore slice preparation. in additional studies, ibogaine (20 mg/kg) enhanced cocaine-inducedreductions throughout serotonin concentration within the nucleus accumbens (rat), an actionattributed to some presynaptic launch mechanism (85,86). However, Sershen et al., (175) reportedwhich cocaine elevated [3H]serotonin efflux throughout striatal slices which efflux was absent withinmice pretreated using both ibogaine or maybe a 5-HT1b agonist. These kinds of later findings ledSershen for you to suggest an action involving ibogaine in the HT1b receptor which is likelyunrelated to the capability associated with cocaine to become able to inhibit serotonin reuptakeblockade (188). Your inhibitory effect of the kappa-opioid agonist U-62066 (1M) in [3H]serotoninrelease throughout striatal slices could possibly be blocked simply by in vivo ibogaine administration(175).

TOP

D. Calcium Regulation.

Ibogaine (80 M) non-competitively antagonized calcium-induced contraction associated with rataorta along with mesenteric artery (138), which usually was interpreted as an action in intracellularcalcium metabolism. Tabernanthine, an alkaloid related to be able to ibogaine, inhibiteddepolarization-stimulated 45Ca influx along with contractions inside the rat aorta (189). Ibogaineinhibited the binding involving [3H]isradipine (an L-type calcium channel blocker) in the mousecerebral cortex with an IC50 associated with ~28 M (11).

TOP

E. Cholinergic Systems.

Ibogaine (at concentrations involving as significantly as 100 M) was reported not to inhibit theparticular binding involving ligands acting with nicotinic or even muscarinic receptors (165).However, subsequent studies demonstrated in which ibogaine inhibited the particular bindingregarding muscarinic M1, M2 as well as M3 ligands at concentrations involving ~ 31, 50 and also12.5 M, respectively (56). Sweetnam et al., (166) showed that ibogaine inhibited radioligandbinding in order to M1, and also M2 receptors along with IC50 values of 5-7 M. These kinds ofauthors additionally reported that ibogaine didn't inhibit the actual binding regarding [3H]NMCI,any nonselective ligand in nicotinic receptors. Ex vivo research has demonstrated that neitheribogaine nor O-desmethylibogaine affect your inhibitory motion in the muscarinic acetylcholine

agonist, carbachol upon adenylyl cyclase exercise in the rat (182).

In a new current study, Badio et al., (125) demonstrated in which ibogaine potently (IC50 ~ twentynM) blocked 22NaCl influx by means of nicotinic receptor channels throughout ratpheochromocytoma cells. This particular effect was seen inside the cells expressing ganglionic,however, not neuromuscular, nicotinic receptor subtypes. This specific inhibition wasnoncompetitive since it had not been overcome simply by growing concentrations regarding agonist.Moreover, the actual blockade had not really been completely reversible, suggesting in whichibogaine could use a long-lasting effect. O-Desmethylibogaine and O-t-butyl-O-desmethylibogainewere 75- and also 20-fold less potent, respectively, than ibogaine in blocking nicotinic receptor-mediated responses. the identical research demonstrated that will ibogaine, as expected to get anoncompetitive blocker, stood a relatively lower affinity (Ki ~ 4 M) as a new possible inhibitor inthe binding of an agonist [3H]nicotine. in support about bat roosting findings, Schneider et al., (190)reported just lately that will ibogaine ( 10 M) had an inhibitory action in nicotinic receptor-mediated catecholamine release in bovine adrenal chromaffin cells. Constant with the Badio et al.,(125) study, these inhibitory outcomes appeared being long-lasting.

TOP

F. Gamma-Aminobutyric Acidergic [GABAergic] Systems.

Two impartial studies (165,166) did not locate virtually any impact regarding ibogaine (atconcentrations associated with as significantly as 100 M) in radioreceptor binding to GABAAreceptors. Inside addition, ibogaine didn't influence 36Cl- uptake through GABA-gated channels(165) as well as GABA-evoked currents throughout rat cultured hippocampal neurons (162).

TOP

G. Voltage-Dependent Sodium Channels.

Ibogaine inhibited (Ki ~ 8.1 M) [3H]batrachotoxin a 20-a-benzoate binding for you to voltage-dependent sodium channels in depolarized mouse neuronal preparations (165). Ibogaine analogs,including ibogamine, tabernanthine and also coronaridine, exhibited potencies much like ibogaine inthis assay.

TOP

H. Glutamatergic Systems.

Our studies (159) indicate which ibogaine is a competitive inhibitor associated with [3H]MK-801binding (Ki ~1 M) to NMDA receptor-coupled ion channels. Within contrast, ibogaine didn't affect[3H]( )- a new -amino-3-hydroxy-5-methylisoxazole-4-pro... acid ([3H]AMPA), [3H]kainate as wellas [3H]glutamate either to the actual NMDA or perhaps metabotropic receptor sites, binding. Thesekinds of findings tend to be constant with a specificity regarding ibogaine with regard to NMDAreceptor-coupled cation channels (159,162,166). The Actual potency involving ibogaine to inhibit[3H]MK-801 binding was also looked at within 8 distinct brain regions of Sprague-Dawley male ratsalong with compared with just about all the dissociation constants with regard to [3H]MK-801estimated making use of saturation analyses. a high correlation (r=0.976, p=0.0004) has beenobtained between the Ki of ibogaine along with Kd associated with [3H]MK-801 over these mindregions (119), steady with all the notion in which these compounds reveal the typical binding site.The Actual capability associated with ibogaine to behave as being a non-competitive NMDA

antagonist can also be demonstrated making use of [3H]1-[1-(2-thienyl)cyclohexyl]piperidin...([3H]TCP), a new thienyl derivative associated with phencyclidine, resulting inside a Ki ~1.5 Minside rat forebrain (119).

Structure-activity studies had been performed using a group of ibogaine analogs, such as theparticular putative ibogaine metabolite O-desmethylibogaine, its metabolic rate resistant analog O---butyl-O-desmethylibogaine, your iboga alkaloids [( )-ibogamine, ( )-coronaridine,tabernanthine], harmaline, and also indolotropanes. Ibogaine was the particular strongest inhibitorof [3H]MK-801 binding (Ki ~ 1.2 M); the particular compounds using the greatest structuralsimilarity to always be able to ibogaine, O-desmethylibogaine along with O-t-buty--O-desmethylibogaine were a smaller sized amount potent (Ki ~ 5.5 along with 179.0 Mrespectively) (72). a ~ 5 fold lower affinity of O-desmethylibogaine compared to ibogaine in [3H]MK-801 binding websites has been furthermore reported by Mash et al., (191).

Consistent using these neurochemical studies, ibogaine produced the voltage-dependent block ofNMDA-evoked currents inside hippocampal cultures (119,162). in addition, ibogaine (100 M) aswell as O-desmethylibogaine (1 mM) blocked the capability associated with NMDA (100 M, 5 sec)to always be able to depolarize frog motoneurons in a non-competitive and also use-dependentmanner (192).

TOP

I. Sigma Receptors.

In our studies (11), ibogaine inhibited [3H]pentazocine (a sigma1 receptor ligand) binding, for you tohigh (IC50 ~86 nM) as well as lower (IC50 ~5.6 M) affinity websites inside mouse cerebellum.Bowen et al., (193) demonstrated that will ibogaine had higher affinity pertaining to sigma2 websites (Ki ~ 200 nM) and low affinity regarding sigma1 sites (Ki ~ 8.5 M), a new ~ 43- foldselectivity pertaining to sigma2 sites. the affinities associated with tabernanthine (13-methoxyibogamine) and ( )-ibogamine pertaining to sigma2 websites had been just like thatrelating to ibogaine. O-Desmethylibogaine, stood a markedly reduced affinity regarding sigma2 websites (Ki ~ 5 M) and within addition lacked affinity pertaining to sigma1 sites. The Actual relatedalkaloids, ( )-coronaridine [( )-18-carbomethoxyibogamine] as well as harmaline lacked affinityfor both sigma receptor subtypes. O-t-Butyl-O-desmethylibogaine inhibited radioligand binding tosigma1 sites having a Ki ~ 3.5 M and sigma2 sites using a Ki ~ 346 nM [c.f. Bowen et al, (72)].The Particular much higher affinity involving ibogaine regarding sigma2 websites compared tosigma1 websites had been also reported through Mach et al., (194). Bowen et al., (195) examinedyour capacity of ibogaine and associated compounds in order to modulate calcium launch fromintracellular shops within indo-1 loaded human SK-N-SH neuroblastoma cells. consistent having itsaffinity with sigma2 sites, ibogaine produced any concentration-dependent increase (13-45%) insideintracellular calcium levels. O-Desmethylibogaine, has been ineffective on this measure inconcentrations as a lot as 100 M. These kind of data claim that the particular shared inside vivoresults of ibogaine and O-desmethylibogaine are nearly all likely not mediated by simply sigma sites.

TOP

J. Miscellaneous Actions regarding Ibogaine.

Deecher et al., (165) reported that will ibogaine (up to one hundred M) did not inhibit radioligandbinding in order to cannabinoid receptors. Ibogaine and O-desmethylibogaine had simply no relationto basal as well as forskolin-stimulated adenylyl cyclase within the rat frontal cortex, midbrain or

even striatum (182). O-Desmethylibogaine, although not ibogaine, produced concentration -dependent increases within the generation of [3H]inositol phosphates that will are not altered byinclusion of tetrodotoxin, cadmium or even omega-conotoxin (196). These kinds of outcomes declarethat the result associated with O-desmethylibogaine upon phosphoinositide hydrolysis was notsecondary for the launch of one as well as much more neurotransmitters. Ali et al., (45) reportedthat ibogaine (0.5-250 M) reduced nitric oxide synthase exercise inside mouse brain; similareffects were noted in the striatum, hippocampus and also cerebellum involving mice handledparenterally with ibogaine (50 mg/kg). Within radioligand binding studies, no impact of ibogainecontinues for you to be entirely on alpha1, alpha2 or perhaps beta1 adrenergic receptors (165).Moreover, ibogaine (20 mg/kg) didn't modify cerebral noradrenaline ranges throughout rats (197).Binienda et al., (140,198) reported in which although ibogaine (50 mg/kg) challenge in rats wasrelated using a decrease in delta, theta, alpha and also beta power spectra associated with corticalEEG in the program of the first 30 min, and subsequent recovery of all except delta bands in thesubsequent 15 min, MK-801 (1 mg/kg) treatment had been followed with a reduction in power of allfour frequency bands for that entire duration of recording. Your selective energy reduction in deltaEEG frequency band of the cortical EEG could suggest your activation involving dopamine receptors.

In the anesthetized rat, ibogaine produced any slight hypoglycemia (60). Right After administrationassociated with 50 mg/kg regarding ibogaine, elevations regarding corticosterone levels had beennoted 15 - 120 min, however, not a day later on (170,171,173). The Actual same dose of ibogainerapidly as well as transiently increased plasma prolactin amounts (171,173). Bunag along withWalaszek (199) reported that ibogaine antagonized the contractile responses produced in guinea pigileum by simply substance P and also angiotensin. Alburges along with Hanson (200) reported whichibogaine administration produced increases involving neurotensin-like immunoreactivity in striatum,nucleus accumbens along with substantia nigra and also substance P -like immunoreactivity withinstriatum and also substantia nigra. Ibogaine or even harmaline suppressed several (T-cell regulatoryand effector, B-cell, and natural killer cell) immune capabilities within vitro (201). Van Beek et al.,(17) reported that ibogaine showed exercise against the gram-positive Bacillus subtilis. Ibogaine didnot alter colonic temperature within mice, nor achieved it affect morphine- or even kappa [U-50,488H]-opioid induced hypothermia (121).

TOP

VIII. CONCLUSIONS.

The renewed curiosity about ibogaine during days gone by decade stems from anecdotal clinicalobservations in which ibogaine supplies a novel means of treating drug addictions. Preclinicalstudies are, within general, consistent using these claims. Thus, ibogaine decreases self-administration involving cocaine and morphine, attenuates morphine withdrawal, along with blocksconditioned location choice produced by simply morphine along with amphetamine. Preclinicalstudies also suggest there's absolutely no abuse liability associated with ibogaine. at doses in whichhinder tolerance and dependence phenomena, mind concentrations regarding ibogaine have reachedranges that will can impact many different neurotransmitter systems. Numerous of those results(e.g., use dependent block associated with NMDA receptor-coupled cation channels, interactionstogether with dopamine transporters as well as kappa opioid receptors) have got previously beenimplicated throughout drug seeking phenomena. However, in the current time, the only mechanismwhich may be invoked to end up being able to explain ibogaine's results about drug seekingphenomena with some certainty will be its ability to inhibit naloxone-precipitated jumping by meansof blockade associated with NMDA receptors. Nonetheless, it's even now uncertain if the anti-addictive properties regarding ibogaine outcome from the single mechanism or are produced atmultiple loci.

The involvement regarding dopaminergic pathways inside drug seeking phenomena can always beviewed dogma, and also ibogaine undoubtedly affects these pathways. Nonetheless, based onavailable data zero distinct picture provides emerged about how this interaction contributes towardsthe anti-addictive properties of ibogaine, or perhaps any other anti-addictive medications. Extrasystematic studies are obviously needed. Anecdotal studies claim long term outcomes of ibogaine indrug seeking next a single administration or perhaps brief course of therapy. This specific claim maybe borne out, a minimal of in part, by simply preclinical studies. Based about these observations, it isunlikely that ibogaine serves merely as substitution therapy. The idea has been hypothesized thatwill a long-lived metabolite is responsible for ibogaine's putative anti-addictive properties,nevertheless further studies are required on this area.

One in the central concerns regarding the particular molecular mechanisms responsible for the anti-addictive actions of ibogaine is regardless of whether or not its NMDA antagonist motion is plentyfor you to explain these effects. Thus, there is an established body associated with preclinical data(and an emerging body of clinical data) demonstrating which NMDA antagonists interrupt drugseeking phenomena to a variety regarding addictive substances. Although it is now more successfulthat ibogaine is a noncompetitive NMDA antagonist (albeit 1000-fold less potent compared toprototype compound, dizocilpine), with the exception involving its capability to block naloxoneprecipitated jumping in morphine-dependent mice, it's uncertain if these outcomes can be attributedto other mechanisms.

Recent structure exercise studies demonstrate which O-desmethylibogaine, which is much lesspotent as compared to ibogaine from NMDA receptors, appears as active as ibogaine within acutelyblocking morphine along with cocaine self-administration. This kind of observation strongly pointstoo various other mechanisms may become operative. a comparable argument can be designed forharmaline, which is somewhat structurally associated in order to ibogaine and also shares a few ofits pharmacological actions (e.g., tremor and also neurotoxic effects, reductions within cocaine aswell as morphine self-administration), nevertheless isn't an NMDA antagonist. Even thoughinhibition associated with drug self-administration by simply harmaline might be thanks in order tounspecific results (e.g., general malaise), these findings nonetheless enhance the possibility whichibogaine's anti-addictive properties might become produced by means of multiple mechanisms. TheParticular involvement of sigma sites over these phenomena appears to become even more obscuresimply because in contrast in order to ibogaine, harmaline features absolutely no appreciable affinitywith sigma web sites whereas O-desmethylibogaine lacks affinity with a sigma2 site, yet all threeblock cocaine along with morphine self-administration.

Ibogaine could affect a number of areas of serotonergic transmission with concentrations that arereadily achieved inside the brain next pharmacologically relevant doses [reviewed simply by Sershenet al., (188)]. Since multiple serotonin receptor subtypes, as well as serotonin reuptake, are usuallymodulated by simply ibogaine, it just isn't shocking the results of this alkaloid on steady stateamounts associated with serotonin as well as its metabolites (whether measured throughout situ orperhaps ex vivo) are complex. Clearly, further studies tend to be required to look at the efficacy ofibogaine as a new possible anti-addictive agent. Similarly, extra preclinical studies is planning to beneeded to elucidate the actual molecular mechanism(s) accountable for these pharmacologicalactions.

TOP

IX. Acknowledgments

The authors thank Dr. H. Sershen with regard to beneficial discussions on the outcomes of ibogaine

upon dopaminergic as well as serotonergic transmission.

TOP

X. REFERENCES

1. A. Lecomte, Arch. Med. Navale 2, 264 (1864).

2. R. Goutarel, O. Gollnhofer, along with R. Sillans, Psychedc Mono. Essays 6, 71 (1993).

3. H.S. Lotsof, U S Patent 4,499,096, (1985).

4. H.S. Lotsof, U S Patent 4,587,243, (1986).

5. H.S. Lotsof, U S Patent 4,857,523, (1989).

6. H.S. Lotsof, U S Patent 5,026,697, (1991).

7. H.S. Lotsof, Bull. MAPS 5, 16 (1995).

8. C.D. Kaplan, E. Ketzer, J. de Jong, along with M. de Vries, Soc. Neurosc. Bull.n 6, six (1993).

9. B. Sisko, Bull. MAPS IV, 15 (1993).

10. P. Popik and also S.D. Glick, Drugs Long Term 21, 1109 (1996).

11. P. Popik, R.T. Layer, and P. Skolnick, Pharmaco. Rev. 47, 235 (1995).

12. W.I. Taylor, within "The Alkaloids. Volume VIII. Chemistry and Physiology" (R.H.F. Manske, ed.),p. 203, Academic Press, New York, London. 1965.

13. W.I. Taylor, within "The Alkaloids. Volume XI. Chemistry as well as Physiology" (R.H.F. Manske,ed.), p. 79, Academic Press, New York, London. 1968.

14. R.E. Schultes as well as A. Hofmann, inside "The Botany and also Chemistry associated withHallucinogens." (R.E. Schultes as well as A. Hofmann, eds.), p. 235 Charles C. Thomas Publisher,Sprinfield. 1980.

15. J.W. Fernandez, "Bwiti - an ethnography of religious imagination in Africa.". Princeton Press.,Princeton, New Jersey, 1982.

16. H.G. Pope, Jr., Econ. Bot. 23, 174 (1969).

17. T.A. Van Beek, C. de Smidt, and also R. Verpoorte, J. Ethnopharmacol. 14, 315 (1985).

18. H. Baillon, Bull. Mens. Soc. Lin. de Paris 1, 782 (1889).

19. J. Dybovsky and also E. Landrin, Acad. Sci. (Paris) 133, 748 (1901).

20. A. Haller and also E. Heckel Compt. Rend. Soc Biol 133, 850 (1901).

21. M. Lambert and also E. Heckel, Compt. Rend. Acad. Sci. 133, 1236 (1901).

22. M. Lambert, Arch. Int. Pharmacodyn. 10, 101 (1902).

23. M.C. Phisalix, Compt. Rend. Soc. Biol. 53, 1077 (1901).

24. G. Pouchet and also J. Chevalier, Bull. Gen. Ther. 149, 211 (1905).

25. E. Rothlin along with M. Raymond-Hamet, Compt. Rend. Soc. Biol. 127, 592 (1938).

26. M. Raymond-Hamet along with E. Rothlin, Arch. Int. Pharmacodyn. Ther. 63, 27 (1939).

27. M. Raymond-Hamet, Compt. Rend. Soc. Biol. 134, 541 (1940).

28. M. Raymond-Hamet, Compt. Rend. Soc. Biol. 133, 426 (1940).

29. M. Raymond-Hamet, Compt. Rend. Soc. Biol. 211, 285 (1940).

30. M. Raymond-Hamet, Compt. Rend. Soc. Biol. 135, 176 (1941).

31. M. Raymond-Hamet, Compt. Rend. Soc. Biol. 212, 768 (1941).

32. M. Raymond-Hamet as well as D. Vincent, Compt. Rend. Soc. Biol. 154, 2223 (1960).

33. C. Naranjo, Clin. Toxicol. 2, 209 (1969).

34. F. De Sio, Medicina Dello Sport 23, 362 (1970).

35. H.S. Lotsof, U S Patent 5,152,994, (1992).

36. L.R. Regan, Justicia September, 1 (1992).

37. N. Touchette, Naturel Med. 1, 288 (1995).

38. FDA Advisory CMTE inside "The NDA Pipeline." (E. Clarke, C. Frederick, as well as K. Balog,eds.), p. V-76 F-D-C Reports, Inc. Chevy Chase, MD, USA. 1993.

39. L.G. Sharpe and J.H. Jaffe, NeuroReport 1, 17 (1990).

40. N. Touchette, J. NIH Res. 5 (November), 50 (1993).

41. J. Buie, Psych. times XI (7), 44 (1994).

42. J. Sanchez-Ramos and D. Mash, Bull. MAPS 4, 11 (1994).

43. S.G. Sheppard, J. Subst. Abuse Treat.11, 379 (1994).

44. B.E. Judd, Ibogaine, psychotherapy, as well as the treatment method involving substance-relateddisorders. Your Eighth International Conference upon Drug-related Harm. (1994).

45. S.F. Ali, S.C. Chetty, X.M. Meng, G.D. Newport, along with W. Slikker, J. Neurochem. 65, S172

(1995).

46. A. Landrin, Bull. Sci. Pharmacol. 11, 319 (1905).

47. W.I. Taylor, J. Am. Chem. Soc. 79, 3298 (1957).

48. G. Bchi, D.L. Coffen, K. Kocsis, P.E. Sonnet, as well as F.E. Ziegler, J. Am. Chem. Soc. 88,3099 (1966).

49. P. Rosenmund, W.H. Haase, J. Bauer, along with R. Frische, Chem. Ber. 180, 1871 (1975).

50. E. Wenkert, D.W. Cochran, H.E. Gottlieb, as well as E.W. Hagaman, Helv. Chim. Acta 59, 2437(1976).

51. H.H. Seltzman, D.F. Odear, F. Ivy Carroll, along with D. Wyrick, J. Chem. Soc. Chem. Commun.1757 (1992).

52. H.H. Seltzman, D.F. Odear, as well as C.P. Laudeman, J. Labled. Compds. Radiopharm. 34(4),367 (1994).

53. S. Budavari, M. O'Neil, A. Smith, P.E. Heckelman, and also J.F. Kinneary, "The Merck Index. AnEncyclopedia associated with Chemicals, Drugs and also Biologicals.". 12th Ed. Merck & Co., Inc.,Whitehouse Station, N.J., USA, 1996.

54. G.P. Cartoni along with A. Giarusso, J. Chromatogr. 71, 154 (1972).

55. J.M. Kelley along with R.H. Adamson, Pharmacol. 10, 28 (1973).

56. D.B. Repke, D.R. Artis, J.T. Nelson, and E.H. Wong, J. Org. Chem. 59, 2164 (1994).

57. H.I. Dhahir, N.C. Jain, and also R.B. Forney, J. Foren. Sci. 16, 103 (1971).

58. H.I. Dhahir, N.C. Jain, and also J.I. Thornton, J. Foren. Sci. 12, 309 (1972).

59. E. Bertol, F. Mari, along with R. Froldi, J. Chromatogr. 117, 239 (1976).

60. H.I. Dhahir, Diss. Abstr. Int. 32/04-B, 2311 (1971).

61. G. Zetler, G. Singbarth, and also L. Schlosser, Pharmacol. 7, 237 (1972).

62. C.A. Gallagher, L.B. Hough, S.M. Keefner, A. Seyed Mozaffari, S. Archer, as well as S.D. Glick,Biochem. Pharmacol. 49, 73 (1995).

63. W.L. Hearn, J. Pablo, G.W. Hime, and D.C. Mash, J. Anal. Toxicol. 19, 427 (1995).

64. M.E. Alburges, R.L. Foltz, along with D.E. Moody, J. Anal. Toxicol. 19, 381 (1995).

65. F.R. Ley, A.R. Jeffcoat, and B. Thomas, J. Chromatogr. A New 723, 101 (1996).

66. S.M. Pearl, L.B. Hough, D.L. Boyd, and S.D. Glick, Pharmacol. Biochem. Behav. 57, 809 (1997).

67. L.B. Hough, S.M. Pearl, as well as S.D. Glick, Existence Sci. 58, PL119 (1996).

68. S.D. Glick, K. Rossman, S. Steindorf, I.M. Maisonneuve, as well as J.N. Carlson, Eur. J.Pharmacol. 195, 341 (1991).

69. I.M. Maisonneuve, K.L. Rossman, R.W. Keller, Jr., as well as S.D. Glick, Mind Res. 575, 69(1992).

70. H. Sershen, A. Hashim, and A. Lajtha, Pharmacol. Biochem. Behav. 47, 13 (1994).

71. I.M. Maisonneuve, R.W. Keller, and S.D. Glick, Eur. J. Pharmacol. 199, 35 (1991).

72. R.T. Layer, P. Skolnick, C.M. Bertha, M.E. Kuehne, and also P. Popik, Eur. J. Pharmacol. 309, 159(1996).

73. D. Mash, J.K. Staley, M.H. Baumann, R.B. Rothman, as well as W.L. Hearn, life Sci. 57, PL45(1995).

74. S.D. Glick, K. Rossman, N.C. Rao, I.M. Maisonneuve, along with J.N. Carlson,Neuropharmacology 31, 497 (1992).

75. G. Chen and B. Bohner, J. Pharmacol. Exp. Ther. 123, 212 (1958).

76. H. Sershen, A. Hashim, L. Harsing, and also A. Lajtha, Existence Sci. 50, 1079 (1992).

77. T. Luxton, L.A. Parker, and also S. Siegel, Prog. Neuro-Psych. Biol. Psych. 20, 857 (1996).